Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.92), $0.16 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $55.6 million versus the consensus estimate of $49.08 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- CTS Corp. (CTS) Tops Q3 EPS by 10c ; Offers Guidance
- Norwood Financial Corp (NWFL) Tops Q3 EPS by 13c
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
